Back to Search
RAYMOND BERGAN MD
MD
Medical Oncology Physician
NPI: 1871569640IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
036-099084(IL)
Education
OTHER
Class of 1987
Research & Publications (20)
Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer.
PMID 11295600·Urology·2001
8-other
MEK4 function, genistein treatment, and invasion of human prostate cancer cells.
PMID 19638505·J Natl Cancer Inst·2009
3-trial
Labeling TiO2 nanoparticles with dyes for optical fluorescence microscopy and determination of TiO2-DNA nanoconjugate stability.
PMID 19242946·Small·2009
8-other
Genistein induces phenotypic reversion of endoglin deficiency in human prostate cancer cells.
PMID 17951357·Mol Pharmacol·2008
8-other
Gadolinium-conjugated TiO2-DNA oligonucleotide nanoconjugates show prolonged intracellular retention period and T1-weighted contrast enhancement in magnetic resonance images.
PMID 18567541·Nanomedicine·2008
8-other
Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells.
PMID 18240292·Mol Carcinog·2008
8-other
Dietary genistein inhibits metastasis of human prostate cancer in mice.
PMID 18339885·Cancer Res·2008
7-preclinical
Associations of serum carotenoid levels with serum insulin-like growth factor-i and insulin-like growth factor binding protein-3 levels in black men and white men.
PMID 18086788·Cancer Epidemiol Biomarkers Prev·2007
4-observational
The methodology used to measure differential gene expression affects the outcome.
PMID 18166675·J Biomol Tech·2007
4-observational
Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway.
PMID 17496924·Oncogene·2007
8-other
A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience.
PMID 17952740·Cancer Invest·2007
3-trial
Genistein inhibits matrix metalloproteinase type 2 activation and prostate cancer cell invasion by blocking the transforming growth factor beta-mediated activation of mitogen-activated protein kinase-activated protein kinase 2-27-kDa heat shock protein pathway.
PMID 16772519·Mol Pharmacol·2006
8-other
Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification.
PMID 16786039·Prostate Cancer Prostatic Dis·2006
4-observational
MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer.
PMID 16407830·Oncogene·2006
8-other
Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
PMID 16615097·Cancer·2006
3-trial
Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells.
PMID 15833883·Cancer Res·2005
8-other
Safety and efficacy of weekly oral oltipraz in chronic smokers.
PMID 15824161·Cancer Epidemiol Biomarkers Prev·2005
3-trial
Gene expression profiling of renal medullary carcinoma: potential clinical relevance.
PMID 14983493·Cancer·2004
5-case
p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion.
PMID 12894225·Oncogene·2003
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 675 N SAINT CLAIR ST, GALTER 21-100
CHICAGO, IL 60611 - Phone
- (312) 695-0990
Quick Facts
- NPI
- 1871569640
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 39
- Publications
- 20
Are you this provider?
Claim Your Profile